NEW ORAL GLP-1 Foundayo is now available as a once-daily oral pill FDA-approved oral GLP-1 Easy, once-daily pill ~11% average weight loss at 72 weeks in Phase 3 trials No injections or refrigeration needed Prescription & ongoing care through Healthspan 1 In Phase 3 trial of adults without diabetes taking the highest dose of Foundayo (orforglipron) alongside diet and exercise
That gap matters, but 15% weight loss still represents a transformative result for most people
Se descubri que tambin tiene efectos en ella
The Fiber Gap Crisis The numbers tell a stark story: while health organizations recommend 25-35 grams of fiber daily, the average American consumes just 10-15 grams
Glucagon-Like Peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: a systematic review of clinical studies and pharmacovigilance reports
Evans J, Collins M, Jennings C, van der Merwe L, Soderstrom I, Olsson T, et al